Akums Drugs and Pharmaceuticals Limited (BOM:544222)

India · Delayed Price · Currency is INR

476.10

-8.10 (-1.67%)

At close: Mar 6, 2026

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
CDMO	34.40B	36.20B	31.21B	29.78B	24.00B
CDMO Growth	-4.96%	15.99%	4.80%	24.04%	-
API	2.77B	2.78B	2.22B	1.36B	6.72M
API Growth	-0.47%	25.26%	63.33%	20151.19%	-
Domestic Branded Formulations	4.34B	3.98B	-	-	-
Domestic Branded Formulations Growth	8.81%	-	-	-	-
International Branded Formulations	1.43B	1.25B	-	-	-
International Branded Formulations Growth	14.26%	-	-	-	-
Trade Generics	1.18B	1.77B	-	-	-
Trade Generics Growth	-33.27%	-	-	-	-
Inter-Segment	-2.93B	-4.20B	-4.43B	-3.45B	-2.64B
Branded and Generic Formulations	-	-	7.55B	9.03B	5.86B
Branded and Generic Formulations Growth	-	-	-16.39%	54.21%	-
Total	41.18B	41.78B	36.55B	36.72B	27.23B
Total Growth	-1.44%	14.32%	-0.46%	34.87%	-

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
India	41.21B	41.82B	36.57B	36.75B	27.26B
India Growth	-1.45%	14.34%	-0.49%	34.81%	-
Total	41.21B	41.82B	36.57B	36.75B	27.26B
Total Growth	-1.45%	14.34%	-0.49%	34.81%	-

Source: S&P Global Market Intelligence.